Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>Sodium butyrate (NaB) in the gut of animals possesses the potential to modulate lipid metabolism, regulate innate immunity, and protect intestinal health. Accumulating data have supported the important function of metabolites of intestinal microflora (MIM) in nonalcoholic fatty liver disease (NAFLD). This study intended to investigate the role of NaB in NAFLD and its specific mechanism.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Mice were fed a high‐fat diet (HFD) for 16 weeks to establish the NAFLD mouse model. Then, the mice were intragastrically administered MIM (200 µL/day) or NaB (200 mg/kg/day) by gavage for another 8 weeks. Then, the morphology of liver tissues was observed by H&E staining, and the lipid deposition of liver tissues was examined by oil red O staining. The NAFLD cell model was constructed in AML12 cells by 24 h of stimulation with 0.5 mM free fatty acids. After treatment with 10 mM NaB, AML12 cells were transfected with mimic‐miR‐150 or inhibitor‐miR‐150. qRT‐PCR and Western blotting were employed to measure the contents of IL‐1β, IL‐6, and TNF‐α and the expression of miR‐150 and CXCR4 in liver tissues of mice and in AML12 cells. A luciferase reporter assay was applied to verify the binding relationship between miR‐150 and CXCR4.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The H&E and oil red O staining results showed hepatic steatosis in the liver tissues of HFD‐fed mice. There were elevated contents of TG, TC, HDL‐C, LDL‐C, and fasting blood glucose, enhanced activities of ALT and AST, increased homeostatic model assessment of insulin resistance scores and increased inflammatory responses in the serum of HFD‐fed mice. However, intervention with MIM or NaB reversed the above trends, indicating that MIM or NaB intervention relieved hepatic steatosis in mice. HFD‐fed mice had downregulated expression of miR‐150, while the expression level was upregulated after MIM or NaB treatment. NaB attenuated NAFLD progression by regulating miR‐150. MiR‐150 can negatively target CXCR4.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>NaB mitigates HFD‐induced NAFLD in mice by upregulating miR‐150 expression to downregulate CXCR4.</p></section>

Butyrate Attenuates Hepatic Steatosis Induced by a High-Fat and Fiber-Deficient Diet via the Hepatic GPR41/43-CaMKII/HDAC1-CREB Pathway

Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet

Butyrate Protects against Diet-Induced NASH and Liver Fibrosis and Suppresses Specific Non-Canonical TGF-β Signaling Pathways in Human Hepatic Stellate Cells

Betaine Alleviates Nonalcoholic Fatty Liver Disease (NAFLD) Via a Manner Involving BHMT/FTO/m6A/ PGC1α Signaling.

Sodium Butyrate Supplementation Inhibits Hepatic Steatosis by Stimulating Liver Kinase B1 and Insulin-Induced Gene

Butyrate Protects Mice Against Methionine–Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels

Sodium Butyrate Attenuates High-Fat Diet-Induced Steatohepatitis in Mice by Improving Gut Microbiota and Gastrointestinal Barrier.

Butyrate protects against high‐fat diet‐induced atherosclerosis via up‐regulating ABCA1 expression in apolipoprotein E‐deficiency mice

Butyrate Alleviates High Fat Diet-induced Obesity Through Enhancement of Mitochondrial Function in The Liver of Mice

Sodium Butyrate Alleviates Fructose-Induced Non-Alcoholic Fatty Liver Disease by Remodeling Gut Microbiota to Promote Γ-Amino Butyric Acid Production

Sodium Butyrate Reduces High-Fat Diet-Induced Non-Alcoholic Steatohepatitis Through Upregulation of Hepatic GLP-1R Expression

Butyrate stimulates hepatic gluconeogenesis in mouse primary hepatocytes

Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis

Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3.

Sodium butyrate ameliorates non‐alcoholic fatty liver disease by upregulating miR‐150 to suppress CXCR4 expression

Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease Through Peroxisome Proliferator-Activated Receptor Α-Mediated Activation of Β Oxidation and Suppression of Inflammation.

Butyrate Stimulates Adipose Lipolysis and Mitochondrial Oxidative Phosphorylation Through Histone Hyperacetylation‐associated Β3‐adrenergic Receptor Activation in High‐fat Diet‐induced Obese Mice

Rectal administration of butyrate ameliorates pulmonary fibrosis in mice through induction of hepatocyte growth factor in the colon via the HDAC-PPARγ pathway

Betaine prevented high-fat diet-induced NAFLD by regulating the FGF10/AMPK signaling pathway in ApoE−/− mice

Regulation of hepatic genes related to lipid metabolism and antioxidant enzymes by sodium butyrate supplementation

Butyrate Alleviates High Fat Diet-Induced Obesity Through Activation of Adiponectin-Mediated Pathway and Stimulation of Mitochondrial Function in the Skeletal Muscle of Mice